Top

Published in:

Open Access 01-10-2014 | Original Article

Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Authors: Kazumasa Komura, Teruo Inamoto, Tomoaki Takai, Taizo Uchimoto, Kenkichi Saito, Naoki Tanda, Junko Kono, Koichiro Minami, Hirohumi Uehara, Yutaka Fujisue, Kiyoshi Takahara, Hajime Hirano, Hayahito Nomi, Toshikazu Watsuji, Satoshi Kiyama, Haruhito Azuma

Published in: World Journal of Urology | Issue 5/2014

Abstract

Purpose

To investigate the treatment outcomes of a single-session high-intensity focused ultrasound (HIFU) using the Sonablate^® for patients with localized prostate cancer.

Methods

Biochemical failure was defined according to the Stuttgart definition [a rise of 1.2 ng/ml or more above the nadir prostate-specific antigen (PSA)] and the Phoenix definition (a rise of 2 ng/ml or more above the nadir PSA). Disease-free survival rate was defined using the Phoenix criteria and positive follow-up biopsy.

Results

A total of 171 patients were identified. Fifty-two (30.4 %) patients were identified to be with D’Amico low risk, 47 (27.5 %) with intermediate risk, and 72 (42.1 %) with high risk. In the median follow-up time of 43 months, there was 44 (25.7 %) and 36 (21.1 %) patients experienced biochemical failure for Stuttgart and Phoenix definition with mean (±SD) time to failure of 17.8 ± 2.1 and 19.4 ± 2.3 months, respectively. A total of 44 (25.7 %) patients were diagnosed as disease failure. Cox multivariate analysis revealed PSA nadir level (PSA cutoff = 0.2 ng/ml; HR = 9.472, 95 % CI 4.527–19.820, p < 0.001) and D’amico risk groups [HR = 3.132 (95 % CI 1.251–6.389), p = 0.033] were the predictor for failure in single-session HIFU.

Conclusions

Single-session HIFU treatment using the Sonablate^® seems to be potentially curative approach. When treated carefully with neoadjuvant hormonal therapy or preoperative transurethral resection of the prostate, higher-risk disease might be able to choose this minimally invasive procedure as primary therapy.

Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123PubMedCrossRefPubMedCentral

Blana A, Murat FJ, Walter B, Thuroff S, Wieland WF, Chaussy C, Gelet A (2008) First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 53:1194–1201PubMedCrossRef

Crouzet S, Rebillard X, Chevallier D, Rischmann P, Pasticier G, Garcia G, Rouviere O, Chapelon JY, Gelet A (2010) Multicentric oncologic outcomes of high-intensity focused ultrasound for localized prostate cancer in 803 patients. Eur Urol 58:559–566PubMedCrossRef

Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A (2011) Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria—analysis from the @-Registry. BJU Int 108:E196–E201PubMedCrossRef

Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL (2003) Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57:915–928PubMedCrossRef

Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF (2009) High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int 104:1058–1062PubMedCrossRef

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef

Pfeiffer D, Berger J, Gross AJ (2012) Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 110:1702–1707PubMedCrossRef

Pinthus JH, Farrokhyar F, Hassouna MM, Woods E, Whelan K, Shayegan B, Orovan WL (2012) Single-session primary high-intensity focused ultrasonography treatment for localized prostate cancer: biochemical outcomes using third generation-based technology. BJU Int 110:1142–1148PubMedCrossRef

10.

D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974PubMedCrossRef

11.

National Comprehensive Cancer Network (2004) Prostate cancer. NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2:224–248

12.

American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035–1041

13.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL (2005) Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol 173:797–802PubMedCrossRef

14.

Patel A, Dorey F, Franklin J, deKernion JB (1997) Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158:1441–1445PubMedCrossRef

15.

Richaud P, Moreau JL, Beuzeboc P, Rebillard X, Villers A, Peyromaure M, Cornud F, Soulie M, Davin JL (2005) Follow-up of prostate cancer. Guidelines of the Comite de Cancerologie de l’Association Francaise d’Urologie. Prog Urol 15:586–592PubMed

16.

Ganzer R, Rogenhofer S, Walter B, Lunz JC, Schostak M, Wieland WF, Blana A (2008) PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer. Eur Urol 53:547–553PubMedCrossRef

17.

Uchida T, Illing RO, Cathcart PJ, Emberton M (2006) To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 98:537–539PubMedCrossRef

18.

Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A (2007) Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer 110:68–80PubMedCrossRefPubMedCentral

19.

Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE (2009) Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75:1350–1356PubMedCrossRef

20.

Rebillard X, Soulie M, Chartier-Kastler E, Davin JL, Mignard JP, Moreau JL, Coulange C (2008) High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology. BJU Int 101:1205–1213PubMedCrossRef

Title: Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy
Authors: Kazumasa Komura
Teruo Inamoto
Tomoaki Takai
Taizo Uchimoto
Kenkichi Saito
Naoki Tanda
Junko Kono
Koichiro Minami
Hirohumi Uehara
Yutaka Fujisue
Kiyoshi Takahara
Hajime Hirano
Hayahito Nomi
Toshikazu Watsuji
Satoshi Kiyama
Haruhito Azuma
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 5/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1215-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Erratum to: Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction

Nocturia: state of the art and critical analysis of current assessment and treatment strategies

Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies

Selective clamping under the usage of near-infrared fluorescence imaging with indocyanine green in robot-assisted partial nephrectomy: a single-surgeon matched-pair study

Analysis of the pentafecta learning curve for laparoscopic radical prostatectomy

Capsular incision in normal prostatic tissue during robot-assisted radical prostatectomy: a new concept or a waste of time?